Pharma forecasting is not a “one and done” activity. The life of a drug – from a glint in the clinician’s eye, to an established therapy heading towards loss of...
Kelly Chamberlain has been with Norstella, Evaluate’s parent company as Partner, Market Intelligence since 2024. She’s an expert in supporting competitive intelligence workflows and ensuring that CI teams can maximize...
CNS may finally be emerging from its long discussed graveyard. Oncology dealmaking is becoming more selective. And sourcing innovation from China is no longer something to be coy about. These...
For the past few years, Melanie Senior and Andreas Hadjivasiliou have worked together to deliver Evaluate’s annual Orphan Drugs report. They charted the rise and rise of drugs for rare...
How do we Create the Analysis for our Orphan Drugs Report? Insight is the cornerstone of our annual orphan drugs report, and all that insight and analysis starts with the...
Orphan drugs are forecast to make up 21% of all prescription drug sales by 2032, according to Evaluate forecasts. So it’s hardly surprising that we had a lot of interest...
